Citations

Mayo Clinic

Showing 10 of 108599 citations.

Magnetic resonance elastography measured shear stiffness as a biomarker of fibrosis in pediatric nonalcoholic fatty liver disease
Schwimmer, Jeffrey B. , Behling, Cynthia , Angeles, Jorge E., Paiz, Melissa, Durelle, Janis, Africa, Jonathan A. , Newton, Kimberly P. , Brunt, Elizabeth M. , Lavine, Joel E. , Abrams, Stephanie H., Masand, Prakash, Krishnamurthy, Rajesh , Wong, Kelvin, Yin, Meng , Glaser, Kevin J. , Wolfson, Tanya, Gamst, Anthony, Hooker, Jonathan , Haufe, William, Schlein, Alexandra , Hamilton, Gavin , Middleton, Michael S. , Dzyubak, Bogdan , Ehman, Richard L. , Hamilton, Gavin , Sirlin, Claude B. , Schwimmer, Jeffrey B , Yin, Meng

Hepatology | May 11, 2017 | Volume: 66 | Issue: 5 | Pages: 1474-1485

10.1002/hep.29241 | PMID 28493388 Get It

Magnetic resonance elastography (MRE) is a promising technique for noninvasive assessment of fibrosis, a major determinant of outcome in nonalcoholic fatty liver disease (NAFLD). However, data in children are limited. The purpose of this study was to determine the accuracy of MRE for the detection of fibrosis and advanced fibrosis in children with NAFLD and to assess agreement between manual and novel automated reading methods. We performed a prospective, multicenter study of two‐dimensional (2D) MRE in children with NAFLD. MR elastograms were analyzed manually at two reading centers, and using a new automated technique. Analysis using each approach was done independently. Correlations were determined between MRE analysis methods and fibrosis stage. Thresholds for classifying the presence of fibrosis and of advanced fibrosis were computed and cross‐validated. In 90 children with a mean age of 13.1 ± 2.4 years, median hepatic stiffness was 2.35 kPa. Stiffness values derived by each reading center were strongly correlated with each other (r = 0.83). All three analyses were significantly correlated with fibrosis stage (center 1, ρ = 0.53; center 2, ρ = 0.55; and automated analysis, ρ = 0.52; P < 0.001). Overall cross‐validated accuracy for detecting any fibrosis was 72.2% for all methods (95% confidence interval [CI], 61.8%‐81.1%). Overall cross‐validated accuracy for assessing advanced fibrosis was 88.9% (95% CI, 80.5%‐94.5%) for center 1, 90.0% (95% CI, 81.9%‐95.3%) for center 2, and 86.7% (95% CI, 77.9%‐92.9%) for automated analysis. Conclusion : 2D MRE can estimate hepatic stiffness in children with NAFLD. Further refinement and validation of automated analysis techniques will be an important step in standardizing MRE. How to best integrate MRE into clinical protocols for the assessment of NAFLD in children will require prospective evaluation. (H epatology 2017;66:1474–1485)
Implementation of Objective PASC-Derived Taxon Demarcation Criteria for Official Classification of Filoviruses
Bào, Yīmíng , Basler, Christopher F. , Bavari, Sina , Bukreyev, Alexander , Chandran, Kartik , Dolnik, Olga , Dye, John M. , Ebihara, Hideki , Formenty, Pierre , Hewson, Roger , Kobinger, Gary , Leroy, Eric M. , Mühlberger, Elke , Sv, Netesov , Patterson, Jean L. , Smither, Sophie J. , Takada, Ayato , Volchkov, Viktor E. , Wahl‐Jensen, Victoria , Kuhn, Jens H. , Amarasinghe, Gaya K. , Paweska, Janusz Tadeusz , Towner, Jonathan S. , Ebihara, Hideki , Mühlberger, Elke

Viruses | May 11, 2017 | Volume: 9 | Issue: 5 | Pages: 106

10.3390/v9050106 | PMID 28492506 Get It

The mononegaviral family Filoviridae has eight members assigned to three genera and seven species. Until now, genus and species demarcation were based on arbitrarily chosen filovirus genome sequence divergence values (≈50% for genera, ≈30% for species) and arbitrarily chosen phenotypic virus or virion characteristics. Here we report filovirus genome sequence-based taxon demarcation criteria using the publicly accessible PAirwise Sequencing Comparison (PASC) tool of the US National Center for Biotechnology Information (Bethesda, MD, USA). Comparison of all available filovirus genomes in GenBank using PASC revealed optimal genus demarcation at the 55–58% sequence diversity threshold range for genera and at the 23–36% sequence diversity threshold range for species. Because these thresholds do not change the current official filovirus classification, these values are now implemented as filovirus taxon demarcation criteria that may solely be used for filovirus classification in case additional data are absent. A near-complete, coding-complete, or complete filovirus genome sequence will now be required to allow official classification of any novel “filovirus.” Classification of filoviruses into existing taxa or determining the need for novel taxa is now straightforward and could even become automated using a presented algorithm/flowchart rooted in RefSeq (type) sequences.
Immunotherapy for Colorectal Cancer
Boland, Patrick M. , Ma, Wen, Ma, Wen Wee

Cancers | May 11, 2017 | Volume: 9 | Issue: 5 | Pages: 50

10.3390/cancers9050050 | PMID 28492495 Get It

The recent success of anti-PD1 drugs in metastatic colorectal cancer patients with mismatch repair deficiency generated overwhelming enthusiasm for immunotherapy in the disease. However, patients with mismatch repair deficient colorectal cancer represent only a small subset of the metastatic population. Current research focuses on advancing immunotherapy to earlier stages of the disease including adjuvant and first-line metastatic settings, and on inducing sensitivity to immune checkpoint inhibitor therapy through a combinatorial approach. Here, we review the contemporary understanding of the immune and molecular landscape in colorectal cancer and discuss ongoing clinical trials evaluating novel combination regimens based on immune checkpoint inhibitors.
Habitual exercise levels are associated with cerebral amyloid load in presymptomatic autosomal dominant Alzheimer's disease
Brown, Belinda M. , Sohrabi, Hamid R. , Taddei, Kevin , Gardener, Samantha L. , Rainey‐Smith, Stephanie R. , Peiffer, Jeremiah J. , Xiong, Chengjie , Fagan, Anne M. , Benzinger, Tammie L.S. , Buckles, Virginia, Erickson, Kirk I. , Clarnette, Roger, Shah, Tejal , Masters, Colin L. , Weiner, Michael W. , Cairns, Nigel J., Rossor, Martin N. , Graff‐Radford, Neill R. , Salloway, Stephen , Vöglein, Jonathan , Laske, Christoph , Noble, James M. , Schofield, Peter R. , Bateman, Randall J. , Morris, John C. , Martins, Ralph N. , Schofield, Peter R , Bateman, Randall J , Masters, Colin L , Vöglein, Jonathan , Benzinger, Tammie L S , Morris, John C , Noble, James M

Alzheimer's & Dementia | May 11, 2017 | Volume: 13 | Issue: 11 | Pages: 1197-1206

10.1016/j.jalz.2017.03.008 | PMID 28501451 Get It

AbstractIntroductionThe objective of this study was to evaluate the relationship between self‐reported exercise levels and Alzheimer's disease (AD) biomarkers, in a cohort of autosomal dominant AD mutation carriers.MethodsIn 139 presymptomatic mutation carriers from the Dominantly Inherited Alzheimer Network, the relationship between self‐reported exercise levels and brain amyloid load, cerebrospinal fluid (CSF) Aβ42, and CSF tau levels was evaluated using linear regression.ResultsNo differences in brain amyloid load, CSF Aβ42, or CSF tau were observed between low and high exercise groups. Nevertheless, when examining only those already accumulating AD pathology (i.e., amyloid positive), low exercisers had higher mean levels of brain amyloid than high exercisers. Furthermore, the interaction between exercise and estimated years from expected symptom onset was a significant predictor of brain amyloid levels.DiscussionOur findings indicate a relationship exists between self‐reported exercise levels and brain amyloid in autosomal dominant AD mutation carriers.
Return to Sport and Clinical Outcomes After Hip Arthroscopic Labral Repair in Young Amateur Athletes: Minimum 2‐Year Follow‐Up
Mohan, Rohith , Johnson, Nick R., Hevesi, Mario , Gibbs, Christopher M. , Levy, Bruce A. , Krych, Aaron J. , Krych, Aaron J , Hevesi, Mario

Arthroscopy | May 11, 2017 | Volume: 33 | Issue: 9 | Pages: 1679-1684

10.1016/j.arthro.2017.03.011 | PMID 28501221 Get It

Purpose To determine the rate of return of young amateur athletes to sport after hip arthroscopy, their clinical outcomes, and pathologic risk factors for worse outcomes 2 years after surgery. Methods This study included all patients between age 13 and 23 who participated in a sport prior to surgery with intent to return who underwent hip arthroscopy after failure of comprehensive nonoperative management for whom 2‐year outcome scores were available. Outcomes collected retrospectively included modified Harris Hip Score (mHHS) and the Hip Outcome Scores (HOS) subscales for activities of daily living (ADL) and sport (HOS Sport). In addition, sport played, return to sport rates, and Tegner Scores were measured preinjury and postoperatively. Descriptive statistics were used to present demographic data. A priori analysis was used to determine the sample size needed to show minimal clinically important differences for mHHS, HOS ADL, and HOS Sport. Results The study population included 50 patients with a mean age of 17.8 years. Athletes returned to sport at a rate of 92% (46/50). At a mean follow‐up of 34 months, the mean mHHS, HOS ADL, and HOS Sport outcome scores were 85, 91, and 80 for the entire study group; 87, 92, and 84 for the group that returned to sport; and 67, 82, and 41 for the group that did not return to sport, respectively. Median preinjury and postoperative Tegner levels were 8 and 7, respectively. Labral takedown and reattachment was associated with lower HOS ADL ( P = .01) and HOS Sport scores ( P = .02). Conclusions Athletes returned to sport at a high rate (92%; 46/50) after hip arthroscopy and perform activities at near preinjury levels. In this group of athletes, arthroscopic labral repair with chondrolabral preservation, which reflected less severe chondrolabral pathology, performed better than labral repair with takedown and reattachment. Level of Evidence Level IV, therapeutic case series.
ATOH1 Promotes Leptomeningeal Dissemination and Metastasis of Sonic Hedgehog Subgroup Medulloblastomas
Grausam, Katie B., Dooyema, Samuel, Bihannic, Laure, Premathilake, Hasitha , Forget, Antoine , Schaefer, Amanda M., Gundelach, Justin H. , Maher, Diane M., Wang, Xin , Heglin, Alex H., Ge, Xijin , Zeng, Erliang , Puget, Stéphanie, Chandrasekar, Indra , Surendran, Kameswaran , Bram, Richard J. , Schüller, Ulrich , Talyor, Michael D., Ayrault, Olivier , Zhao, Haotian , Taylor, Michael D. , Macura, Slobodan , Morrissy, A. Sorana

Cancer Research | May 11, 2017 | Volume: 77 | Issue: 14 | Pages: 3766-3777

10.1158/0008-5472.can-16-1836 | PMID 28490517 Get It

Abstract Medulloblastoma arising from the cerebellum is the most common pediatric brain malignancy, with leptomeningeal metastases often present at diagnosis and recurrence associated with poor clinical outcome. In this study, we used mouse medulloblastoma models to explore the relationship of tumor pathophysiology and dysregulated expression of the NOTCH pathway transcription factor ATOH1, which is present in aggressive medulloblastoma subtypes driven by aberrant Sonic Hedgehog/Patched (SHH/PTCH) signaling. In experiments with conditional ATOH1 mouse mutants crossed to Ptch1+/− mice, which develop SHH-driven medulloblastoma, animals with Atoh1 transgene expression developed highly penetrant medulloblastoma at a young age with extensive leptomeningeal disease and metastasis to the spinal cord and brain, resembling xenografts of human SHH medulloblastoma. Metastatic tumors retained abnormal SHH signaling like tumor xenografts. Conversely, ATOH1 expression was detected consistently in recurrent and metastatic SHH medulloblastoma. Chromatin immunoprecipitation sequencing and gene expression profiling identified candidate ATOH1 targets in tumor cells involved in development and tumorigenesis. Among these targets specific to metastatic tumors, there was an enrichment in those implicated in extracellular matrix remodeling activity, cytoskeletal network and interaction with microenvironment, indicating a shift in transcriptomic and epigenomic landscapes during metastasis. Treatment with bone morphogenetic protein or SHH pathway inhibitors decreased tumor cell proliferation and suppressed metastatic tumor growth, respectively. Our work reveals a dynamic ATOH1-driven molecular cascade underlying medulloblastoma metastasis that offers possible therapeutic opportunities. Cancer Res; 77(14); 3766–77. ©2017 AACR.
Cryo-EM structure of human adenovirus D26 reveals the conservation of structural organization among human adenoviruses
Yu, Xiaodi , Campbell, Melody G. , Barry, Mary E., Asturias, Francisco J. , Barry, Michael A. , Reddy, Vijay , Veesler, David , Barry, Michael A , Campbell, Melody G

Science Advances | May 11, 2017 | Volume: 3 | Issue: 5 | Pages: No page available

10.1126/sciadv.1602670 | PMID 28508067 Get It

Near-atomic resolution structure of species-D adenovirus 26 (HAdV-D26) reveals structural conservation among human adenoviruses.
Multiple‐dose ponezumab for mild‐to‐moderate Alzheimer's disease: Safety and efficacy
Landen, Jaren W., Cohen, Sharon , Billing, Clare B., Cronenberger, Carol, Styren, Scot, Burstein, Aaron H. , Sattler, Catherine, Kantarci, Kejal , Schwartz, Pamela F., Duggan, William, Zhao, Qinying, Sprenger, Ken, Bednar, Martin M., Binneman, Brendon, Lee, Jae‐Hong , Jack, Clifford R. , Kantarci, Kejal

Alzheimer's & Dementia: Translational Research & Clinical Interventions | May 11, 2017 | Volume: 3 | Issue: 3 | Pages: 339-347

10.1016/j.trci.2017.04.003 | PMID 29067341 Get It

Abstract Introduction Multiple intravenous doses of ponezumab, an anti‐amyloid antibody, were evaluated in subjects with mild‐to‐moderate Alzheimer's disease (AD). Methods In part A, 77 subjects were randomized to ponezumab 0.1, 0.5, or 1 mg/kg (75 treated) and 26 to placebo (24 treated). In part B, 63 subjects were randomized and treated with ponezumab 3 or 8.5 mg/kg and 32 with placebo. Subjects received 10 infusions over 18 months and were followed for 6 months thereafter. Results Ponezumab was generally safe and well tolerated. Most common adverse events were fall (16.7% ponezumab, 21.4% placebo), headache (13.8%, 21.4%), and cerebral microhemorrhage (13.8%, 19.6%). Plasma ponezumab increased dose‐dependently with limited accumulation. Cerebrospinal fluid penetration was low. Plasma Aβ 1–x and Aβ 1–40 showed robust increases, but cerebrospinal fluid biomarkers showed no dose response. Ponezumab had no effects on cognitive/functional outcomes or brain volume. Conclusions Multiple‐dose ponezumab was generally safe, but not efficacious, in mild‐to‐moderate AD.
The BRCA1 c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium
Moghadasi, Setareh , Vreeswijk, Maaike P.G. , Janssen, Linda AM, Borg, Åke , Ehrencrona, Hans , Paulsson-Karlsson, Ylva, Wappenschmidt, Barbara , Engel, Christoph , Gehrig, Andrea, Hansen, Thomas van Overeem , Thomassen, Mads , Jensen, Uffe Birk , Kruse, Torben A., Ejlertsen, Bent , Gerdes, Anne‐Marie , Pedersen, Inge Søkilde , Caputo, Sandrine M. , Couch, Fergus J., Hallberg, Emily J., Ouweland, Ans MW van den, Collée, Margriet J., Teugels, Erik , Adank, Muriel A. , Luijt, Rob B. van der , Mensenkamp, Arjen R. , Oosterwijk, Jan C., Blok, Marinus J. , Janin, Nicolas, Claes, Kathleen , Tucker, Kathy , Viassolo, Valeria , Eccles, Diana , Devilee, Peter , Asperen, Christi J. van , Goldgar, David E., Gómez, E. , Meeks, Huong , Janssen, Linda A.M., Arnold, Norbert , Collée, Margriet , Toland, Amanda Ewart , Spurdle, Amanda B. , Eccles, Diana , Vreeswijk, Maaike P G , Claes, Kathleen B M , Ehrencrona, Hans , van der Luijt, Rob B , Engel, Christoph , van Asperen, Christi J , Gómez-García, Encarna B , Hansen, Thomas van Overeem , Devilee, Peter

Journal of Medical Genetics | May 11, 2017 | Volume: 55 | Issue: 1 | Pages: 15-20

10.1136/jmedgenet-2017-104560 | PMID 28490613 Get It

Background We previously showed that the BRCA1 variant c.5096G>A p.Arg1699Gln (R1699Q) was associated with an intermediate risk of breast cancer (BC) and ovarian cancer (OC). This study aimed to assess these cancer risks for R1699Q carriers in a larger cohort, including follow-up of previously studied families, to further define cancer risks and to propose adjusted clinical management of female BRCA1*R1699Q carriers. Methods Data were collected from 129 BRCA1*R1699Q families ascertained internationally by ENIGMA (Evidence-based Network for the Interpretation of Germline Mutant Alleles) consortium members. A modified segregation analysis was used to calculate BC and OC risks. Relative risks were calculated under both monogenic model and major gene plus polygenic model assumptions. Results In this cohort the cumulative risk of BC and OC by age 70 years was 20% and 6%, respectively. The relative risk for developing cancer was higher when using a model that included the effects of both the R1699Q variant and a residual polygenic component compared with monogenic model (for BC 3.67 vs 2.83, and for OC 6.41 vs 5.83). Conclusion Our results confirm that BRCA1*R1699Q confers an intermediate risk for BC and OC. Breast surveillance for female carriers based on mammogram annually from age 40 is advised. Bilateral salpingo-oophorectomy should be considered based on family history.
Towards the Future Development of an Electrochemical Continuous Multimarker Biosensor for Enhanced Glycemic Management
Lin, Chi, Probst, David , Honikel, Mackenzie M. , Belle, Jeffrey T. La , La Belle, Jeffrey T, Malkoc, Aldin

Journal of Diabetes Science and Technology | May 11, 2017 | Volume: 11 | Issue: 5 | Pages: 1053-1054

10.1177/1932296817707543 | PMID 28490199 Get It